Wang Xin, Palaskas Nicolas L, Hobbs Brian P, Abe Jun-Ichi, Nead Kevin T, Yusuf Syed Wamique, Hermann Joerg, Deswal Anita, Lin Steven H
Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
Department of Radiation Oncology, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Tianjin 300060, China.
Cancers (Basel). 2022 Mar 3;14(5):1304. doi: 10.3390/cancers14051304.
Background: There is a paucity of data regarding the association between radiation exposure of heart substructures and the incidence of major coronary events (MCEs) in patients with esophageal cancer (ESOC) undergoing chemoradiation therapy. We studied radiation dosimetric determinants of MCE risk and measured their impact on patient prognosis using a cohort of ESOC patients treated at a single institution. Methods: Between March 2005 and October 2015, 355 ESOC patients treated with concurrent chemoradiotherapy were identified from a prospectively maintained and institutional-regulatory-board-approved clinical database. Dose-distribution parameters of the whole heart, the atria, the ventricles, the left main coronary artery, and three main coronary arteries were extracted for analysis. Results: Within a median follow-up time of 67 months, 14 patients experienced MCEs at a median of 16 months. The incidence of MCEs was significantly associated with the left anterior descending coronary artery (LAD) receiving ≥30 Gy (V30Gy) (p = 0.048). Patients receiving LAD V30Gy ≥ 10% of volume experienced a higher incidence of MCEs versus the LAD V30Gy < 10% group (p = 0.044). The relative rate of death increased with the left main coronary artery (LMA) mean dose (Gy) (p = 0.002). Furthermore, a mutual promotion effect of hyperlipidemia and RT on MCEs was observed. Conclusion: Radiation dose to coronary substructures is associated with MCEs and overall survival in patients with ESOC. In this study, the doses to these substructures appeared to be better predictors of toxicity outcomes than mean heart dose (MHD) or whole-heart V30Gy. These findings have implications for reducing coronary events through radiation therapy planning.
关于接受放化疗的食管癌(ESOC)患者心脏亚结构的辐射暴露与主要冠状动脉事件(MCE)发生率之间的关联,数据较少。我们使用在单一机构接受治疗的ESOC患者队列,研究了MCE风险的辐射剂量学决定因素,并评估了它们对患者预后的影响。方法:2005年3月至2015年10月期间,从一个前瞻性维护且经机构监管委员会批准的临床数据库中,识别出355例接受同步放化疗的ESOC患者。提取全心、心房、心室、左冠状动脉主干和三条主要冠状动脉的剂量分布参数进行分析。结果:在中位随访时间67个月内,14例患者发生MCE,中位时间为16个月。MCE的发生率与左前降支冠状动脉(LAD)接受≥30 Gy(V30Gy)显著相关(p = 0.048)。LAD V30Gy≥体积10%的患者与LAD V30Gy<10%的组相比,MCE发生率更高(p = 0.044)。死亡相对率随左冠状动脉主干(LMA)平均剂量(Gy)增加(p = 0.002)。此外,观察到高脂血症和放疗对MCE有相互促进作用。结论:ESOC患者冠状动脉亚结构的辐射剂量与MCE和总生存期相关。在本研究中,这些亚结构的剂量似乎比平均心脏剂量(MHD)或全心V30Gy更能预测毒性结果。这些发现对通过放疗计划减少冠状动脉事件具有重要意义。